Lexeo Therapeutics Q4 2025 Earnings Report

Lexeo Therapeutics EPS Results

• Actual EPS: -$0.27
• Consensus EPS: -$0.32
• Beat/Miss: Beat by +$0.05
• One Year Ago EPS: N/A

Lexeo Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Lexeo Therapeutics Announcement Details

• Quarter: Q4 2025
• Date: 3/30/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Lexeo Therapeutics (NASDAQ:LXEO) is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments. Lexeo’s lead programs are designed to optimize receptor selectivity and pharmacokinetics, with the goal of delivering rapid onset of action and durable therapeutic benefits in both inpatient and outpatient settings.

To advance its clinical development efforts, Lexeo collaborates with academic institutions and contract research organizations across North America and Europe. These partnerships support ongoing Phase 1 and Phase 2 studies, as well as formulation and biomarker development activities that underpin the company’s regulatory strategy.

Headquartered in the United States, Lexeo Therapeutics is led by a management team with extensive experience in neuroscience research, drug development and regulatory affairs. The company aims to address significant unmet needs in mental health by translating cutting‐edge science into safe, effective treatments for patients worldwide.